CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This study involves evaluating a combination of chemotherapy drugs known as "CLAG-GO"
[cladribine, cytarabine, granulocyte-colony stimulating factor (G-CSF) and gemtuzumab
ozogamicin (GO)] in the treatment of acute myeloid leukemia (AML) that has not responded well
to standard therapy or has returned after an initial remission (relapsed). The trial will be
conducted at the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC).
Potential participants will go through a screening period to see if they are eligible to join
the study. If eligible, participants will be hospitalized for 4-5 weeks to receive study
treatment with CLAG-GO, called induction chemotherapy. If tests show that the cancer is in
remission after induction chemotherapy, participants may undergo further chemotherapy (known
as consolidation) or may proceed with bone marrow/stem cell transplantation. Patients who
receive consolidation chemotherapy and remain in remission may have up to 8 cycles of
outpatient maintenance therapy. A cycle lasts about 28 days. All participants will be
monitored carefully for both side effects and to see if the study treatment is working. Lab
tests and exams will be conducted throughout the entire study. In addition, special studies
will be done at various time points to try to understand better how the drugs work and which
patients are likely to respond best.